Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Publication date
2020-07
Authors
Verheijen, R B
Swart, E L
Beijnen, Jos
Schellens, Johannes
Huitema, A D R
Steeghs, N
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 https://doi-org.proxy.library.uu.nl/10.1007/s00280-017-3463-x
Keywords
Taverne, SDG 3 - Good Health and Well-being
Citation
Verheijen, R B, Swart, E L, Beijnen, J H, Schellens, J H M, Huitema, A D R & Steeghs, N 2020, 'Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization', Cancer Chemotherapy and Pharmacology, vol. 86, no. 1, 163. https://doi.org/10.1007/s00280-020-04090-4